Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of test doses of HM10460A on the duration
of severe neutropenia (DSN) during Cycle 1 in patients with breast cancer who are candidates
for adjuvant or neoadjuvant chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Treatments:
Cyclophosphamide Docetaxel Immunoglobulin Fc Fragments